Top 10 Real-World Evidence Platforms for 2026

The real-world evidence platform market has moved from strategic novelty to standard operating procedure. By one industry estimate, the global RWE solutions market now exceeds $4.7 billion and is projected to grow at a compound annual rate above 14% through the end of the decade and the vendor landscape underneath that growth has consolidated hard in the past year. Datavant completed its acquisition of Aetion in July 2025, combining a tokenization and linkage platform with a regulatory-grade causal-inference engine into a single vendor accepted by both FDA and EMA. Roche has acquired both TriNetX and Flatiron Health. Paradigm Health picked up Flatiron's clinical research business in early 2026. The RWE platform a sponsor evaluated eighteen months ago may not be the same company, or even the same product, today.

That consolidation makes vendor selection harder, not easier and it's exactly why choosing the right real-world evidence platform now requires understanding which specific evidence job each vendor is actually built for. This guide covers the ten real-world evidence platforms life sciences and clinical research teams are shortlisting most in 2026.

What Is a Real-World Evidence Platform?

A real-world evidence platform turns real-world data EHRs, claims, registries, lab and pharmacy data into the analytical output sponsors actually need: a comparative effectiveness study, a natural history study, an external control arm, a payer dossier, or a post-market safety signal. The distinction that matters is between a real-world data provider (the source) and a real-world evidence platform (the analytical layer that turns that data into a defensible conclusion). Some vendors do both under one roof; others specialize in one and rely on data partners or tokenization vendors for the other.

Why RWE Platform Choice Matters More in 2026

Two regulatory shifts are raising the stakes on platform selection this year. In December 2025, the FDA finalized updated real-world evidence guidance for medical device submissions, and in March 2026 it adopted ICH M14, the harmonized international standard (developed with EMA and PMDA) for how non-interventional RWD studies are designed, analyzed, and reported for drug safety assessment. Both push the same requirement down into vendor selection: an RWE platform now has to demonstrate not just that its underlying data is comprehensive, but that every clinical fact used in an analysis is traceable to its source, dated, and reconcilable when data sources disagree.

That's a materially higher bar than "how many lives does your dataset cover," and it's why buyer's guides in this space increasingly conclude that no single RWE platform is the right answer for every study most sponsors that succeed with real-world evidence combine two or three complementary platforms rather than standardizing on one vendor for every therapeutic area and evidence type.

Top 10 Real-World Evidence Platforms for 2026

1. NeuroDiscovery AI

NeuroDiscovery AI approaches real-world evidence generation the way most of the platforms below approach oncology: as a therapeutic-area specialty rather than a checkbox. Built on a longitudinal dataset of 6M+ patient records and 3M+ active patients across 1,000+ providers and 100+ clinical sites in 16+ states, the platform uses NeuroLLM™ to extract disease staging, cognitive assessment scores, and functional outcome measures from unstructured neurology documentation the same category of clinical detail that, industry-wide, structured EHR fields and diagnosis codes are known to capture only a small fraction of. For evidence questions in Alzheimer's, Parkinson's, epilepsy, and dementia natural history studies, external control arms, post-market surveillance that means an evidence base built from data structured specifically for how neurological disease actually gets documented, rather than a general claims-and-EHR feed applied to neurology after the fact.

Best for: sponsors generating real-world evidence in neurology and neurodegenerative disease, where eligibility and outcomes detail lives disproportionately in unstructured clinical notes.

2. IQVIA

IQVIA remains the largest and broadest real-world evidence platform in the market, combining global claims and EHR data with regulatory science consulting and commercial analytics under one roof. Its scale is the point: for sponsors executing multi-country evidence programs across many therapeutic areas simultaneously, IQVIA is typically the default option, with top-20 pharma accounts running data and services contracts worth several million dollars annually.

Best for: large, multi-country evidence generation programs spanning many therapeutic areas.

3. Aetion (Datavant)

Now part of Datavant following its July 2025 acquisition, the Aetion Evidence Platform™ is built specifically for regulatory-grade causal inference pre-specified protocols, documented analytical parameters, and audit trails designed to withstand FDA and EMA scrutiny. The combination with Datavant's tokenization and linkage infrastructure gives sponsors a single vendor spanning both data linkage and the analytical methodology layer, backed by a network of 300+ data partners accepted by both agencies.

Best for: regulatory submissions and payer evidence that require transparent, reproducible causal-inference methodology, not just data access.

4. Flatiron Health

Flatiron's oncology-specific EHR network has tripled in scale, now spanning 30+ academic medical centers across the US, UK, Germany, and Japan, with a dataset encompassing 5+ million patient records and 1.5 billion data points. Its curated approach of clinical abstraction from unstructured oncology notes rather than raw structured export is what makes it the default reference dataset for oncology real-world evidence specifically.

Best for: oncology real-world evidence built on curated, clinically abstracted EHR data rather than claims alone.

5. ICON Real World Solutions

ICON connects clinical trial data directly with real-world outcomes through its Real World Solutions division, running epidemiological, safety, and market access research across therapeutic areas as part of a broader CRO relationship. Because ICON already runs trials for many sponsors, it's a natural fit for programs that want trial and post-market evidence generation coordinated by a single organization rather than handed off between vendors.

Best for: sponsors who want trial data and real-world evidence generation managed within one CRO relationship across the product lifecycle.

6. Komodo Health

Komodo's all-payer claims network and conversational-AI analytics layer make it a common choice for epidemiology, treatment-pattern research, and safety surveillance at scale, particularly where breadth of longitudinal patient-journey coverage matters more than clinical-note-level detail. It's also a frequent choice for rare-disease cohort identification, where its all-payer design helps surface small populations that narrower networks miss.

Best for: epidemiology, market access, and safety surveillance work that depends on broad, claims-based longitudinal coverage.

7. HealthVerity

HealthVerity operates as a data marketplace and identity-management layer, letting sponsors construct custom linked datasets across a wide range of data partners rather than working from one fixed data asset. Its privacy-preserving linkage technology and governance model are built specifically to support the kind of custom, study-specific data assembly that a fixed dataset can't flex to match.

Best for: studies that need a custom-assembled dataset spanning multiple data types and sources rather than a single vendor's fixed data asset.

8. OM1

OM1 pairs an AI-driven real-world data cloud with predictive modeling focused on specialty and chronic conditions, using its Patient Finder tool to identify patients with a high likelihood of a target condition across integrated clinical, claims, and pharmacy data. Its specialty-condition focus overlaps with some neurological indications, though its model spans many specialty areas rather than being purpose-built around neurology's specific documentation patterns.

Best for: specialty and chronic-condition evidence generation where predictive patient identification across mixed data types is the core need.

9. TriNetX

TriNetX runs a federated network model, letting researchers query de-identified EHR data directly across participating health systems without centralizing patient-level data and it has become the most-cited real-world data source in peer-reviewed research, with more than 2,000 citations. Now under Roche ownership following its 2025 acquisition, it remains widely used for cohort feasibility and comparative-outcomes research across a broad range of conditions.

Best for: rapid, federated cohort queries and comparative-outcomes research across a large multi-health-system network.

10. Panalgo

Panalgo's Instant Health Data (IHD) platform is built around a different problem than data access: speed and accessibility of analysis. It converts claims, EHR, and registry data into a unified, analysis-ready format with a healthcare-specific data model, point-and-click analytics, and a generative-AI assistant (Ella AI) for cohort building aimed at teams who need to run rigorous real-world analyses without a dedicated programming team for every study.

Best for: life sciences teams that need to run real-world analyses quickly and repeatably without heavy custom programming for each study.

Why Neurology Needs a Real-World Evidence Platform of Its Own

Every platform above is built to serve real-world evidence generation across a wide span of therapeutic areas which is exactly why most are strongest where clinical facts map cleanly to structured fields, as they largely do in oncology's staging systems and claims-heavy epidemiology work. Neurology doesn't have that structural advantage. Disease progression in conditions like Parkinson's and Alzheimer's is tracked through rating scales, cognitive assessments, and caregiver-reported functional status that are recorded almost entirely as free text the same category of clinical documentation that, industry-wide, structured coding is known to capture only a small fraction of.

That gap is precisely what the FDA's new data-provenance requirements are now forcing every RWE platform to confront directly, and it's the reason a neurology-specific evidence platform, built around extracting structured clinical variables from neurology's own documentation patterns rather than a general oncology- or claims-oriented model, produces a meaningfully more complete evidence base for neurological and neurodegenerative disease programs.

How to Choose the Right Real-World Evidence Platform

• Data provider or evidence platform or both? Some vendors supply raw linked data; others do the analytical and methodological work. Know which one you're buying, and whether it satisfies your regulatory submission's provenance requirements on its own.
• What's the submission track record for your specific use case? RWE has supported more than 250 medical device authorizations and over 35 drug and biologic applications since 2016 ask any shortlisted vendor for precedent matched to your agency and evidence type, not just aggregate patient counts.
• How does it handle unstructured clinical data? Given the FDA's emphasis on tracing individual clinical facts to their source, ask exactly how a platform extracts and validates information from clinical notes rather than accepting "AI-enabled" as a sufficient answer.
• Is your therapeutic area a specialty or a checkbox? A platform that lists broad therapeutic-area coverage is not the same as one whose underlying data model and extraction methodology were built around your specific disease category.
• Does recent consolidation affect who you're actually contracting with? With Datavant/Aetion and Roche/TriNetX/Flatiron now under common ownership, confirm what a merger changes about data access terms, methodology continuity, and long-term product roadmap before signing.

Common Features to Look for in an RWE Platform

• Documented data provenance, traceable to source for individual clinical facts rather than dataset-level completeness alone
• Pre-specified, transparent analytical methodology, with audit trails suitable for regulatory or payer scrutiny
• Validated extraction from unstructured clinical data, with disclosed accuracy benchmarks
• Regulatory submission precedent matched to your specific agency and evidence type
• Therapeutic-area-specific data modeling, not a one-size-fits-all schema applied uniformly across every disease category

Final Thoughts

The real-world evidence platform market in 2026 looks different than it did even a year ago fewer independent vendors, higher regulatory expectations for data provenance, and a growing recognition that most sponsors need a portfolio of platforms rather than a single vendor for every evidence question. IQVIA, Aetion, Flatiron Health, ICON, Komodo Health, HealthVerity, OM1, TriNetX, and Panalgo each solve a specific piece of that puzzle well across a broad range of therapeutic areas and evidence types. For neurology and neurodegenerative disease programs specifically, where outcomes and disease-progression detail live disproportionately in unstructured clinical notes, a purpose-built platform like NeuroDiscovery AI is increasingly the more defensible foundation for evidence generation.